.Focus on: Malaria

The launch of the Millennium Development Goals (MDGs) in 2000 served as a catalyst for significant advancements in malaria control and elimination. Through great international efforts, the malaria-specific target (MDG 6C: Have halted by 2015 and begun to reverse the incidence of malaria and other major diseases) has been met.

Since then, in May 2015, the WHO Global Technical Strategy for Malaria 2016-2030 was adopted at the World Health Assembly. The strategy intends to guide and support regional and country programmes as they work towards malaria control and elimination.

The Strategy sets ambitious but achievable global targets, including:

  • Reducing malaria case incidence by at least 90% by 2030.
  • Reducing malaria mortality rates by at least 90% by 2030.
  • Eliminating malaria in at least 35 countries by 2030.
  • Preventing a resurgence of malaria in all countries that are malaria-free.

Remarkable progress has been made in reducing the global burden of this disease and IFPMA member companies recognize the imminent need to overcome emerging challenges that may hinder the current momentum or even derail progress.  

The research-based pharmaceutical industry recognizes that malaria elimination requires action from all angles. The research-based pharmaceutical industry recognizes that malaria elimination requires action from all angles. Copyright IFPMA

Malaria Today

Many countries have made malaria elimination a priority, and dramatically expanded and intensified their efforts to fight the disease. As a result, between 2010 and 2015 malaria incidence among populations at risk fell by 21% globally and malaria mortality rates among populations at risk fell by 29% globally.

Malaria, a parasite transmitted from the bites of infected mosquitoes, is still one of the world’s biggest killers. According to the latest WHO estimates, released in December 2016, there were 212 million cases of malaria in 2015 and 429 000 deaths. Though preventable and curable, malaria mostly takes the lives of pregnant women and children. Sub-Saharan Africa carries a disproportionately high share of the global malaria burden. In 2015, the region was home to 90% of malaria cases and 92% of malaria deaths. In Southeast Asia a more deadly form of the parasite, resistant to artemisinin, the key ingredient in most effective malaria treatments, is increasing in numbers and spreading across borders.  

Doing our part – discovery, development and distribution

IFPMA endorses the World Health Organization’s Global Malaria Programme (GMP) and its partner the Roll Back Malaria Partnership. The research-based pharmaceutical industry recognizes that malaria elimination requires action from all angles, from increased access to treatments, improved education and training of health workers and the research and development of new medicines and vaccines.

IFPMA member companies have 53 R&D projects in the pipeline for malaria, one of which is at Phase 3 level of development. The research-based pharmaceutical industry identifies R&D collaboration as an instrumental tool by which to combat one of the most pressing global health challenges. To allow for stakeholders to draw on their respective resources and experiences to optimize results, IFPMA companies are partnering with 26 partners including national governments, research institutes, product development partnerships (PDPs) and NGOs that deal with malaria medicines and vaccine innovation, many of them focusing on combating antimalarial or insecticide resistance. 

These partnerships include the Tres Cantos Open Lab of GlaxoSmithKline for drug discovery, the Novartis Malaria Initiative and the contributions of the R&D pharmaceutical industry to the Medicines for Malaria Venture (MMV).

Though research and development plays a key role in attainment of a world free of malaria, increasing prevention interventions and access to malaria diagnosis, effective case management and treatment is another core objective for IFPMA member companies. Innovative partnerships in this area include the SMS for Life partnership to prevent medicine stock outs, maternal health training programs for nurses and midwives so that they are better equipped to detect malaria and the Power of One Campaign which donates annually 1 million antimalarial treatments in Zambia.


You can learn more about these programs and many others by following the link “Malaria” under Partnership Information to the right.

Join us in conversations around malaria using the hashtags #healthpartnerships, #malaria and #endmalaria on social media.  

More information can be found here:

Partnership information

Therapeutic Focus Infectious Diseases

Disease(s) Malaria

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa, North America, South Asia, Sub-Saharan Africa

Number of Countries 198

Country(ies) Afghanistan, Albania, Algeria, Andorra, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Cook Islands, Costa Rica, Côte d'Ivoire, Croatia, Cuba, Cyprus, Czech Republic, Democratic Republic of the Congo, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Ethiopia, Fiji, Finland, France, French Guiana, Gabon, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hong-Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kuwait, Kyrgyzstan, Lao PDR, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Macedonia, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, Niue, North Korea, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Samoa, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Korea, South Sudan, Spain, Sri Lanka, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Sudan, Suriname, Swaziland, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, The Gambia, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Tuvalu, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States of America, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe

Start Date 2000

Anticipated completion date Ongoing